JP2018509890A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509890A5 JP2018509890A5 JP2017540262A JP2017540262A JP2018509890A5 JP 2018509890 A5 JP2018509890 A5 JP 2018509890A5 JP 2017540262 A JP2017540262 A JP 2017540262A JP 2017540262 A JP2017540262 A JP 2017540262A JP 2018509890 A5 JP2018509890 A5 JP 2018509890A5
- Authority
- JP
- Japan
- Prior art keywords
- δ133p53β
- isoform
- δ133p53γ
- pluripotent stem
- induced pluripotent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000001708 Protein Isoforms Human genes 0.000 claims 22
- 108010029485 Protein Isoforms Proteins 0.000 claims 22
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 19
- 238000000034 method Methods 0.000 claims 11
- 210000001082 somatic cell Anatomy 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 210000002950 fibroblast Anatomy 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000008672 reprogramming Effects 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 230000002463 transducing effect Effects 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010010099 Combined immunodeficiency Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 208000011345 Duchenne and Becker muscular dystrophy Diseases 0.000 claims 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 208000028735 Gaucher disease type III Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229910003460 diamond Inorganic materials 0.000 claims 1
- 239000010432 diamond Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000002242 embryoid body Anatomy 0.000 claims 1
- 230000007717 exclusion Effects 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 238000003306 harvesting Methods 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305145 | 2015-01-30 | ||
| EP15305145.3 | 2015-01-30 | ||
| PCT/EP2016/052085 WO2016120493A1 (en) | 2015-01-30 | 2016-02-01 | Reprogramming method for producing induced pluripotent stem cells (ipsc) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018509890A JP2018509890A (ja) | 2018-04-12 |
| JP2018509890A5 true JP2018509890A5 (enExample) | 2019-03-14 |
Family
ID=52589314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540262A Pending JP2018509890A (ja) | 2015-01-30 | 2016-02-01 | 人工多能性幹細胞（ｉＰＳＣ）の生産を再プログラムする方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10767165B2 (enExample) |
| EP (1) | EP3250679B1 (enExample) |
| JP (1) | JP2018509890A (enExample) |
| WO (1) | WO2016120493A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3510146B1 (en) | 2016-09-12 | 2026-02-11 | President and Fellows of Harvard College | Transcription factors controlling differentiation of stem cells |
| CA3038721A1 (en) * | 2016-09-30 | 2018-04-05 | Mayo Foundation For Medical Education And Research | Viral vectors for nuclear reprogramming |
| US20200063105A1 (en) * | 2017-05-01 | 2020-02-27 | President And Fellows Of Harvard College | Transcription factors controlling differentiation of stem cells |
| GB2564437B (en) | 2017-07-10 | 2020-11-04 | Univ Brunel | Method of testing a gene therapy vector using induced pluripotent stem cells |
| US12031153B2 (en) | 2017-12-01 | 2024-07-09 | President And Fellows Of Harvard College | Methods and compositions for the production of oligodendrocyte progenitor cells |
| WO2019195675A1 (en) | 2018-04-06 | 2019-10-10 | President And Fellows Of Harvard College | Methods of identifying combinations of transcription factors |
| EP3976096A4 (en) * | 2019-05-30 | 2023-11-08 | Immunolux International Corp. | USE OF SMALLPOX VIRUS WITH AUTOLOGENOUSLY INDUCED PLURIPOTENT STEM CELLS FOR VACCINATION AND DISEASE THERAPY |
| SG11202113095PA (en) | 2019-05-31 | 2021-12-30 | Harvard College | Sox9-induced oligodendrocyte progenitor cells |
| GB201909975D0 (en) * | 2019-07-11 | 2019-08-28 | Babraham Inst | Novel reprogramming method |
| US20220273591A1 (en) * | 2019-07-26 | 2022-09-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining risk of developing insulin resistance |
| CN114736872A (zh) * | 2022-05-06 | 2022-07-12 | 中国科学院动物研究所 | 提高多能干细胞性能的组合物、方法及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5951254B2 (ja) * | 2008-03-17 | 2016-07-13 | ザ スクリプス リサーチ インスティテュート | 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法 |
| KR101606943B1 (ko) * | 2008-06-27 | 2016-03-28 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 유도된 다능성 줄기 세포의 효율적인 확립 방법 |
| WO2010033991A2 (en) * | 2008-09-22 | 2010-03-25 | Children's Medical Center Corporation | Detection of human somatic cell reprogramming |
| EP2272979A1 (en) * | 2009-06-30 | 2011-01-12 | Centre National de la Recherche Scientifique (CNRS) | Method for testing a subject thought to be predisposed to having cancer |
| WO2011016588A1 (en) * | 2009-08-07 | 2011-02-10 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
| AU2011308567B2 (en) | 2010-10-01 | 2015-09-03 | Fundacion Centro Nacional De Investigaciones Oncologicas, Carlos Iii | Manipulation of stem cell function by p53 isoforms |
| CA2973942C (en) * | 2015-01-30 | 2023-07-11 | Centre National De La Recherche Scientifique (Cnrs) | Delta133p53beta and delta133p53gamma isoforms are biomarkers of cancer stem cells |
-
2016
- 2016-02-01 JP JP2017540262A patent/JP2018509890A/ja active Pending
- 2016-02-01 EP EP16702146.8A patent/EP3250679B1/en active Active
- 2016-02-01 US US15/547,212 patent/US10767165B2/en active Active
- 2016-02-01 WO PCT/EP2016/052085 patent/WO2016120493A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Leng et al. | Molecular imaging for assessment of mesenchymal stem cells mediated breast cancer therapy | |
| Terai et al. | Immortalization of human fetal cells: the life span of umbilical cord blood-derived cells can be prolonged without manipulating p16INK4a/RB braking pathway | |
| Mende et al. | CCND1–CDK4–mediated cell cycle progression provides a competitive advantage for human hematopoietic stem cells in vivo | |
| US20220401491A1 (en) | Mesenchymal stem cell expressing trail and cd, and use thereof | |
| TWI614340B (zh) | 體幹細胞及其製備方法 | |
| JP7449648B2 (ja) | リプログラミング前駆体組成物およびその使用方法 | |
| Islam et al. | CCR6 functions as a new coreceptor for limited primary human and simian immunodeficiency viruses | |
| TW202140779A (zh) | 唾液酸酶至癌細胞、免疫細胞及腫瘤微環境之輸送 | |
| Chen et al. | miR-19a/19b improves the therapeutic potential of mesenchymal stem cells in a mouse model of myocardial infarction | |
| JP2013530965A5 (enExample) | ||
| Hausburg et al. | Defining optimized properties of modified mRNA to enhance virus-and DNA-independent protein expression in adult stem cells and fibroblasts | |
| Doering | Retroviral modification of mesenchymal stem cells for gene therapy of hemophilia | |
| Jahangiri et al. | Interleukin-12 inhibits tumor growth and metastasis promoted by tumor-associated mesenchymal stem cells in triple-negative breast cancer | |
| Zhang et al. | Avian influenza virus infection induces differential expression of genes in chicken kidney | |
| JP7798762B2 (ja) | Ｈｉｖ感染症を治療するための長寿命ｔ細胞 | |
| WO2004029301A3 (en) | Method for assaying replication of hbv and testing susceptibility to drugs | |
| Tang et al. | NKG2D-CAR-targeted iPSC-derived MSCs efficiently target solid tumors expressing NKG2D ligand | |
| Rani et al. | Intronic alternative polyadenylation in the middle of the DMD gene produces half-size N-terminal dystrophin with a potential implication of ECG abnormalities of DMD patients | |
| CN104711240B (zh) | 禽呼肠孤病毒σA蛋白及其相关生物材料的应用 | |
| JP2016511636A (ja) | 消化管間質腫瘍（ｇｉｓｔ）を治療する方法及び組成物 | |
| CN104762274B (zh) | 禽呼肠孤病毒σNS蛋白及其相关生物材料的应用 | |
| Qian et al. | Lentivirus‐modified human umbilical cord mesenchymal stem cells maintain their pluripotency | |
| CA3254576A1 (en) | METHODS FOR EVALUATING MODIFIED RETRONIC ACTIVITY AND THEIR USES | |
| Zhao et al. | Adenovirus E1A TRRAP-targeting domain-mediated enhancement of MYC association with the NuA4 complex activates a panel of MYC target genes enriched for gene expression and ribosome biogenesis | |
| JP7116280B2 (ja) | ゲノムサイトの可視化標識方法及びその細胞と生体の老化レベル検出への応用 |